Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier
The blood-brain barrier (BBB) largely excludes antibodies from entering the central nervous system, thus limiting the potential of therapeutic antibodies to treat conditions such as neurodegenerative diseases and neuro-psychiatric disorders. Here, we demonstrate that the transport of human antibodie...
Saved in:
| Main Authors: | Jason Tien, Dmitri Leonoudakis, Ralitsa Petrova, Vivian Trinh, Tetsuya Taura, Debapriya Sengupta, Lisa Jo, Angela Sho, Yong Yun, Eric Doan, Anita Jamin, Hussein Hallak, David S. Wilson, Jennifer R. Stratton |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2229098 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies
by: SuBin Lee, et al.
Published: (2025-07-01) -
The FcRn from gene to protein and function: comparison between species
by: Luz Belinda Ortiz-Alegría, et al.
Published: (2025-08-01) -
Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice
by: Kenta Haraya, et al.
Published: (2025-12-01) -
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01) -
Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential
by: Sanghwan Ko, et al.
Published: (2025-04-01)